Patents by Inventor Stefan Kiesgen

Stefan Kiesgen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Construct for the delivery of a molecule into the cytoplasm of a cell
    Patent number: 10442863
    Abstract: Described is a construct comprising (a) a targeting moiety; (b) a fusogenic moiety consisting one or more fusogenic sequence(s) derived from dengue virus glycoprotein E comprising the sequence DRGWGNGCGLFGKGGI (SEQ ID NO:1) or a sequence which shows 1 to 8 substitutions, deletions, or insertions in comparison to SEQ ID NO:1; and (c) a molecule which is to be delivered into the cytoplasm of a cell. Moreover, described is a pharmaceutical composition comprising the construct according to the invention and optionally a pharmaceutical acceptable carrier. Further, described is a kit comprising one or more fusogenic sequence(s) derived from dengue virus glycoprotein E comprising the sequence as shown in SEQ ID NO:1 or a sequence which shows 1 to 8 substitutions, deletions, or insertions in comparison to SEQ ID NO:1.
    Type: Grant
    Filed: September 7, 2015
    Date of Patent: October 15, 2019
    Assignee: Lutana GMBH
    Inventors: Michaela Arndt, Jürgen Krauss, Stefan Kiesgen
  • CONSTRUCT FOR THE DELIVERY OF A MOLECULE INTO THE CYTOPLASM OF A CELL
    Publication number: 20170260274
    Abstract: Described is a construct comprising (a) a targeting moiety; (b) a fusogenic moiety consisting one or more fusogenic sequence(s) derived from dengue virus glycoprotein E comprising the sequence DRGWGNGCGLFGKGGI (SEQ ID NO:1) or a sequence which shows 1 to 8 substitutions, deletions, or insertions in comparison to SEQ ID NO:1; and (c) a molecule which is to be delivered into the cytoplasm of a cell. Moreover, described is a pharmaceutical composition comprising the construct according to the invention and optionally a pharmaceutical acceptable carrier. Further, described is a kit comprising one or more fusogenic sequence(s) derived from dengue virus glycoprotein E comprising the sequence as shown in SEQ ID NO:1 or a sequence which shows 1 to 8 substitutions, deletions, or insertions in comparison to SEQ ID NO:1.
    Type: Application
    Filed: September 7, 2015
    Publication date: September 14, 2017
    Inventors: Michaela Arndt, Jürgen Krauss, Stefan Kiesgen